Corcept Therapeutics (CORT) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached $207.6 million, up 13.8% year-over-year, driven by hypercortisolism business growth and record new prescriptions.

• Net income declined to $19.7 million from $47.2 million in Q3 2024, primarily due to higher operating expenses related to R&D and product launches.

• Strong growth in hypercortisolism segment, with a 42.5% increase in tablets shipped and expanded prescriber base.

• Pipeline advanced with two NDAs for relacorilant under FDA review and expanded oncology and metabolic disease programs.

• Transition to new pharmacy partners underway to address capacity constraints, with additional pharmacies planned for 2026.

Financial highlights

• Q3 2025 product revenue was $207.6 million, up from $182.5 million in Q3 2024.

• Net income for Q3 2025 was $19.7 million, down from $47.2 million year-over-year.

• Cash and investments totaled $524.2 million as of September 30, 2025, after $50–$50.6 million in stock repurchases.

• Operating expenses increased to $197.4 million in Q3 2025, mainly due to R&D and SG&A for new product launches.

• Gross margin remained high, with cost of sales at 2.2% of revenue for Q3 2025.

Outlook and guidance

• 2025 revenue guidance updated to $800–$850 million, reflecting capacity constraints and anticipated demand.

• Anticipation of FDA approval for relacorilant in hypercortisolism by December 30, 2025, and in ovarian cancer by July 2026.

• Additional specialty pharmacies to be added to support growth and meet demand.

• Relacorilant projected to generate $3–$5 billion in annual revenue in hypercortisolism within 3–5 years.

• R&D spending expected to remain flat in 2026; SG&A to increase with new launches and clinical studies.